Key terms

About APLS

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest APLS news

Today 6:45am ET Wells Fargo Remains a Hold on Apellis Pharmaceuticals (APLS) by TipRanks Today 1:10am ET Analysts Conflicted on These Healthcare Names: Enliven Therapeutics (ELVN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS) by TipRanks Apr 15 6:20am ET Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Rewalk Robotics (LFWD) and Apellis Pharmaceuticals (APLS) by TipRanks Apr 09 6:40am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD) by TipRanks Mar 29 4:30am ET Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Apellis Pharmaceuticals (APLS) by TipRanks Mar 29 4:20am ET Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Bluebird Bio (BLUE) by TipRanks Mar 19 7:10am ET Analysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Apellis Pharmaceuticals (APLS) and Ultragenyx Pharmaceutical (RARE) by TipRanks Mar 11 7:09am ET Apellis appoints Philip Ferrone as chief medical retina advisor by TipRanks Mar 07 12:00am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Laboratory (LH), Apellis Pharmaceuticals (APLS) and Iovance Biotherapeutics (IOVA) by TipRanks Mar 04 7:10am ET EyePoint appoints Ribeiro as Chief Medical Officer by TipRanks Mar 04 6:27am ET Apellis price target raised to $89 from $87 at UBS by TipRanks Feb 28 11:59am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Feb 28 11:59am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Feb 28 8:44am ET Apellis price target raised to $67 from $60 at Wedbush by TipRanks Feb 28 7:40am ET Apellis price target raised to $84 from $77 at BofA by TipRanks Feb 28 6:55am ET Apellis price target raised to $100 from $81 at Baird by TipRanks Feb 28 6:36am ET Buy Rating Affirmed for Apellis Pharmaceuticals Amid Strong Syfovre Performance and Expanding Market Opportunities by TipRanks Feb 28 5:48am ET Buy Rating Affirmed for Apellis Pharmaceuticals Amid Strong Syfovre Sales and Expanding Market Potential by TipRanks Feb 28 12:05am ET Maintaining Hold on Apellis Pharmaceuticals Amid Syfovre’s Uncertain EMA Approval Prospects by TipRanks Feb 27 1:15pm ET Strong Syfovre Sales Drive Buy Recommendation for Apellis Pharmaceuticals with Revised $85 Price Target by TipRanks Feb 27 1:00pm ET Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Denali Therapeutics (DNLI) by TipRanks Feb 27 7:09am ET Apellis expects cash to fund expenditures for ‘foreseeable future’ by TipRanks Feb 27 7:08am ET Apellis reports Q4 EPS (73c), consensus (69c) by TipRanks Feb 15 6:46am ET Apellis price target raised to $60 from $49 at Mizuho by TipRanks Feb 07 11:01am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Feb 07 8:38am ET Apellis Pharmaceuticals Outperforms Astellas: A Strong Buy Recommendation by TipRanks Feb 05 11:25am ET Apellis price target raised to $110 from $106 at Raymond James by TipRanks Feb 05 4:37am ET Apellis upgraded to Buy from Hold at Jefferies by TipRanks Jan 30 6:36am ET Apellis price target raised to $79 from $75 at Oppenheimer by TipRanks Jan 29 5:07am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), Dexcom (DXCM) and Nanosonics Limited (OtherNNCSF) by TipRanks Jan 27 10:36am ET Maintaining Buy Rating on Apellis Pharmaceuticals Amidst European Setback and Promising U.S. Market Prospects by TipRanks

No recent press releases are available for APLS

APLS Financials

1-year income & revenue

Key terms

APLS Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

APLS Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

NEW YORK, NEW YORK - FEBRUARY 08: A New York Community Bank stands in Brooklyn on February 08, 2024 in New York City. New York Community Bancorp, a regional lender, shed about 60% of its value over the past eight days and its credit rating has been downgraded to Junk by Moody's. (Photo by Spencer Platt/Getty Images)
Spencer Platt/Getty Images
US regional banks are still under pressure. That’s likely to continue
Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming